Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.
about
Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors?Mu-opioid antagonists for opioid-induced bowel dysfunctionShort-term elevation of intracranial pressure does neither influence duodenal motility nor frequency of bolus transport events: a porcine model.Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndromeOpioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individualsAvicenna's View on the Etiologies of Intestinal ObstructionOpioid-induced constipation: advances and clinical guidanceIntractable restless legs syndrome: role of prolonged-release oxycodone-naloxoneEvolving paradigms in the treatment of opioid-induced bowel dysfunctionConsensus Recommendations on Initiating Prescription Therapies for Opioid-Induced ConstipationThe Useage of Opioids and their Adverse Effects in Gastrointestinal Practice: A ReviewClinical potential of naloxegol in the management of opioid-induced bowel dysfunctionChronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunitiesOpioid-induced bowel dysfunction: prevalence, pathophysiology and burdenAlvimopanTreatment of opioid-induced gut dysfunctionOpioid induced bowel disease: a twenty-first century physicians' dilemma. Considering pathophysiology and treatment strategiesDevelopment of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids[Is the pharmacological treatment of constipation in palliative care evidence based? : a systematic literature review].Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.Intravenous lidocaine for effective pain relief after inguinal herniorrhaphy: a prospective, randomized, double-blind, placebo-controlled study.Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain.Opioid-induced constipation: pathophysiology, clinical consequences, and management.Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials.Managing opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide.Oxycodone/Naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrenceMethylnaltrexone: the evidence for its use in the management of opioid-induced constipation.micro-Opioid receptor stimulation in the medial subnucleus of the tractus solitarius inhibits gastric tone and motility by reducing local GABA activity.Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain.Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer.Intraperitoneal bupivacaine effect on postoperative nausea and vomiting following laparoscopic cholecystectomy.Opioid-induced mitogen-activated protein kinase signaling in rat enteric neurons following chronic morphine treatment.Recent advances in the use of opioids for cancer painAdverse events associated with sedatives, analgesics, and other drugs that provide patient comfort in the intensive care unit.Perioperative acupuncture and related techniques.Pain management in trauma: A review studyEfficacy and tolerability of low-dose oral prolonged-release oxycodone/naloxone for chronic nononcological pain in older patientsQuality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxoneA randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain.Opiate-induced oesophageal dysmotility.
P2860
Q21261900-22C30947-B2FA-4740-83D9-F56CFC2C948FQ24243268-FB3547E8-CA1A-4326-B168-F44F7568FF9FQ25255044-19505D7F-BD4B-4FD6-8090-65A26F3421C6Q26743440-95FA18B8-6A0C-401D-BB27-64B217EBB631Q26745747-6834B78B-57F0-41DF-BB3D-E7A6EFF5F280Q26750621-FB66F130-76CA-4121-BC66-6814CA206AFBQ26765571-FC93FFE4-EAFB-4D08-9C8B-2ECADE2F4FD5Q26766416-1DDDE9AC-C03B-45A6-96C3-411914E57C77Q26777692-35C2CAE0-32B8-4FE5-90E8-ED1988DABC23Q26830397-F8B58477-514E-493C-8404-8A232741354BQ26851158-BF23FE66-3ADB-40B9-8BE9-5FE60392218DQ26995944-FBF1E2C0-FE06-444B-A1CE-0890ADC9DB9FQ28083547-43C43483-0CEA-4997-B025-CA89C52E8CD2Q28209970-B51C4F83-BA12-42F2-8994-CA25D18490B4Q28249359-D6AFA6DC-5C62-46CB-9D97-337421A8237DQ28284578-38B3276C-FB6B-4226-8DBE-D0CAA372E117Q28294194-1CFDACBD-6735-4686-8A10-0A4BC6748D60Q30989361-8EE93B10-C509-48D8-AD6D-7840C78A5203Q31104772-5892E8DA-27DF-40A1-8D5B-0B64C734BF74Q33296232-94D08F16-7055-4939-A9B6-3BF33CE1C802Q33450820-5EF70908-FEAB-4CA4-A6C2-6E13DB17154BQ33520508-B45EC743-4808-4BF0-A1FF-1DDA7F9697ADQ33635040-0899F8F2-EC9D-46A4-8C1A-57D8B50FD62FQ33709851-4B5D5C7C-C4E5-4BD4-A642-707D27A237A5Q33715430-B848C61B-C4AB-4373-90AC-D6DE55AD44E3Q33938740-B0D5A21A-0E45-49F2-95CB-0844EAA781CBQ33973870-C940CE5B-968D-444C-8ED1-6DB7F284905FQ34085287-913C93EF-648E-44DC-AD59-899EAF7C757CQ34167814-94191E24-B3F7-4315-9DFA-E38570AB9892Q34170592-1518A43B-7AE6-466D-9351-64A12C49FA76Q34186342-C2AAD404-2709-4129-B89F-692381B1B9D4Q34323667-FFE25B42-31E7-4751-97E2-A287163D8C67Q34418203-0018EBCC-5C54-4D78-8318-F44636A5C400Q34419506-B54E3BAA-E338-40C6-93DC-666897CA9FACQ34667060-80B31689-D101-44C3-BF17-FE208D4D27CFQ34677848-89DE0E97-0D78-4BD3-B9D1-D9D8D50FE9C9Q34787421-4BEB2D10-3B4F-4F13-A9CE-5BFB784EFB45Q34798408-32AC49AE-19EE-424C-9D47-EE8E952F5FE0Q34805216-8B75190C-6FD1-4415-B820-1CB647F8981EQ34973933-27FB58AB-7F59-457F-81C3-C98C8530CDE7
P2860
Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.
@ast
Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.
@en
type
label
Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.
@ast
Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.
@en
prefLabel
Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.
@ast
Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.
@en
P1433
P1476
Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.
@en
P304
P356
10.2165/00003495-200363070-00003
P577
2003-01-01T00:00:00Z
P6179
1019595718